Alexandria Venture Investments is among the investors supporting the immunotherapy developer focused on cancer, autoimmune and infectious diseases.

US-based immunotherapy developer Asher Biotherapeutics closed a $108m series B round featuring Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, yesterday.

The round also included Wellington Management Company, RA Capital Management, Marshall Wace, Logos Capital, Invus, Janus Henderson Investors, Boxer Capital, Mission BioCapital, Third Rock Ventures and undisclosed institutional investors.

Founded in 2019, Asher Bio focuses on developing targeted immunotherapy treatments for cancer, autoimmune and infectious diseases, selectively activating certain…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn